Kesmalea Therapeutics key facts
- Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation.
- Kesmalea Therapeutics’s last known valuation is $39.0M.
- It has raised $37.8M; the latest was Early Stage VC ($12.9M) in Aug 2024.
- Notable investors include Oxford Science Enterprises, BioInnovation Institute, Syncona.
- Status: Privately Held (backing).
Who backs Kesmalea Therapeutics
3- ·Watch Kesmalea Therapeutics: the Monday email on marks, rounds and moves
Kesmalea Therapeutics funding rounds
No funding rounds for Kesmalea Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Kesmalea Therapeutics valuation
Kesmalea Therapeutics's last known valuation is $39 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Kesmalea Therapeutics investors
3 investors are on record for Kesmalea Therapeutics, including Oxford Science Enterprises, BioInnovation Institute and Syncona.
About Kesmalea Therapeutics
Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation. The company's platform enables the creation of oral, CNS-penetrant degraders by inserting reversible linkers, allowing patients with chronic diseases such as oncology and CNS disorders to access innovative treatments.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 24
- Website
- kesmalea.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kesmalea Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.